A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.

Wael A. Harb, Srinivasu Poondru, Hal W. Hirte et al.|Journal of Clinical Oncology|2011

Cited by 7